Lincoln Pharmaceuticals Ltd Stock Price Today (NSE: LINCOLN)
Fundamental Score
Lincoln Pharmaceuticals Ltd Share Price Live NSE/BSE & Institutional Fundamental Analysis
Lincoln Pharmaceuticals Ltd share price today is ₹615.70, up +0.00% on NSE/BSE as of 17 February 2026. Lincoln Pharmaceuticals Ltd (LINCOLN) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.01K (Cr). The 52-week high for LINCOLN share price is ₹N/A and the 52-week low is ₹N/A. At a P/E ratio of 12.68x, LINCOLN is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 12.82% and a debt-to-equity ratio of 0.00.
Lincoln Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Lincoln Pharmaceuticals Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Financial Analysis: Lincoln Pharmaceuticals Share Price
The pharmaceutical sector, often driven by innovation and patent exclusivity, can experience significant volatility linked to drug development pipelines and regulatory approvals. This analysis provides an observational overview of Lincoln Pharmaceuticals share price and its financial health, based on a snapshot of available data. The current price is ₹459.799988, accompanied by a Price-to-Earnings (PE) ratio of 12.68 and a Return on Capital Employed (ROCE) of 17.28%.
The PE ratio of 12.68 suggests that investors are paying ₹12.68 for every rupee of Lincoln Pharmaceuticals' earnings. This valuation metric needs careful interpretation when benchmarked against its sector peers. For instance, comparing Lincoln Pharmaceuticals Ltd with peers like
Mankind Pharma Ltd, a comprehensive assessment should include evaluating management quality, which is crucial for navigating regulatory landscapes and fostering innovation. A deeper investigation into management's strategic decisions and track record would be beneficial for a more nuanced comparison.A key strength for Lincoln Pharmaceuticals appears to be its ROCE of 17.28%. ROCE measures how efficiently a company is using its capital to generate profits. A higher ROCE, like Lincoln's, indicates superior profitability and suggests a potential economic moat. This moat, reflecting a competitive advantage, might stem from factors like cost leadership, differentiated products, or brand recognition. However, sustaining this level of ROCE requires continuous investment in innovation and efficient capital management.
This observational analysis is a component of a comprehensive 80-parameter fundamental audit, verifying factors related to the business, and conducted under the guidance of Sweta Mishra. It’s important to note that this is a purely descriptive assessment of publicly available information and does not constitute investment advice. Investors should conduct their own thorough research and consult with a qualified financial advisor before making any investment decisions regarding Lincoln Pharmaceuticals or any other security.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Lincoln Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LINCOLN across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Excellent ROCE Performance (17.28%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (18.17%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 12.68 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (71.86x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹214.56 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Profit Decline Concern (-24.12%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Limited Institutional Interest (FII+DII: 4.74%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Lincoln Pharmaceuticals Ltd Financial Statements
Comprehensive financial data for Lincoln Pharmaceuticals Ltd including income statement, balance sheet and cash flow
About LINCOLN (Lincoln Pharmaceuticals Ltd)
Lincoln Pharmaceuticals Ltd (LINCOLN) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Pharmaceuticals sector with a current market capitalisation of ₹1.01K (Cr). Lincoln Pharmaceuticals Ltd has delivered a Return on Equity (ROE) of 12.82% and a ROCE of 17.28%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking LINCOLN share price can monitor key metrics including P/E ratio, promoter holding of 49.78%, and quarterly earnings growth.
Company Details
Key Leadership
Corporate Events
LINCOLN Share Price: Frequently Asked Questions
What is the current share price of Lincoln Pharmaceuticals Ltd (LINCOLN)?
As of 17 Feb 2026, 10:14 am IST, Lincoln Pharmaceuticals Ltd share price is ₹615.70. The LINCOLN stock has a market capitalisation of ₹1.01K (Cr) on NSE/BSE.
Is LINCOLN share price Overvalued or Undervalued?
LINCOLN share price is currently trading at a P/E ratio of 12.68x, compared to the industry average of 31.77x. Based on this relative valuation, the Lincoln Pharmaceuticals Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of LINCOLN share price?
The 52-week high of LINCOLN share price is ₹N/A and the 52-week low is ₹N/A.
What factors affect the Lincoln Pharmaceuticals Ltd share price?
Key factors influencing LINCOLN share price include quarterly earnings growth (Sales Growth: 1.33%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Lincoln Pharmaceuticals Ltd a good stock for long-term investment?
Lincoln Pharmaceuticals Ltd shows a 5-year Profit Growth of 9.50% and an ROE of 12.82%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in LINCOLN shares.
How does Lincoln Pharmaceuticals Ltd compare with its industry peers?
Lincoln Pharmaceuticals Ltd competes with major peers in the Pharmaceuticals. Investors should compare LINCOLN share price P/E of 12.68x and ROE of 12.82% against the industry averages to determine competitive standing.
What is the P/E ratio of LINCOLN and what does it mean?
LINCOLN share price has a P/E ratio of 12.68x compared to the industry average of 31.77x. Investors pay ₹13 for every ₹1 of annual earnings.
How is LINCOLN performing according to Bull Run's analysis?
LINCOLN has a Bull Run fundamental score of 51.5/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does LINCOLN belong to?
LINCOLN operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Lincoln Pharmaceuticals Ltd share price.
What is Return on Equity (ROE) and why is it important for LINCOLN?
LINCOLN has an ROE of 12.82%, which shows decent profitability but room for improvement. ROE measures how efficiently Lincoln Pharmaceuticals Ltd generates profits from shareholders capital.
How is LINCOLN debt-to-equity ratio and what does it indicate?
LINCOLN has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is LINCOLN dividend yield and is it a good dividend stock?
LINCOLN offers a dividend yield of 0.36%, meaning you receive ₹0.36 annual dividend for every ₹100 invested in Lincoln Pharmaceuticals Ltd shares.
How has LINCOLN share price grown over the past 5 years?
LINCOLN has achieved 5-year growth rates of: Sales Growth 10.03%, Profit Growth 9.50%, and EPS Growth 9.47%.
What is the promoter holding in LINCOLN and why does it matter?
Promoters hold 49.78% of LINCOLN shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Lincoln Pharmaceuticals Ltd.
What is LINCOLN market capitalisation category?
LINCOLN has a market capitalisation of ₹1015 crores, placing it in the Small-cap category.
How volatile is LINCOLN stock?
LINCOLN has a beta of N/A. A beta > 1 suggests the Lincoln Pharmaceuticals Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is LINCOLN operating profit margin trend?
LINCOLN has a 5-year average Operating Profit Margin (OPM) of 18.17%, indicating the company's operational efficiency.
How is LINCOLN quarterly performance?
Recent quarterly performance shows Lincoln Pharmaceuticals Ltd YoY Sales Growth of 1.33% and YoY Profit Growth of -24.12%.
What is the institutional holding pattern in LINCOLN?
LINCOLN has FII holding of 4.73% and DII holding of 0.01%. Significant institutional holding often suggests professional confidence in the Lincoln Pharmaceuticals Ltd stock.